Rituxan
FDA Approves Riabni, Third Biosimilar to Rituxan
The FDA Approved Amgen's Riabni, the 3rd biosimilar to the originator, U.S.-licensed Rituxan.
DECEMBER 18, 2020
FDA Approves Pfizer Biosimilar to Rituxan
Rituximab-pvvr is a monoclonal antibody that works by targeting a protein called CD20, which is present on the ...
JULY 24, 2019
FDA Approves Truxima, First Biosimilar to Rituxan
Truxima can be used to treat three types of adults with non-Hodgkin lymphoma.
NOVEMBER 29, 2018
Rituxan Hycela Approved for FL, DLBCL, CLL
Rituximab and hyaluronidase human (Rituxan Hycela, Genentech) was approved for subcutaneous injection for the ...
JUNE 23, 2017
Load more